Memantine Grindeks

Memantine, the active ingredient in Memantine Grindeks, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, helping to preserve cognition and daily functioning.

GNH USA supplies Memantine Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent batch release, regulatory support, and on‑time delivery across multiple regions.

Memantine is used in the management of Alzheimer’s disease, targeting glutamatergic excitotoxicity.

- Moderate to severe Alzheimer’s disease: improves cognitive function and daily living activities. - Mild‑to‑moderate Alzheimer’s disease (as adjunct therapy): may help maintain cognition when combined with cholinesterase inhibitors. - Behavioral disturbances in Alzheimer’s disease: can reduce agitation and aggression in some patients.

Memantine may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Dizziness - Headache - Constipation

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (e.g., anaphylaxis, rash) - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When prescribing memantine, clinicians should consider several safety precautions to minimize risk. - Renal impairment: adjust dose or monitor renal function closely. - Hepatic disease: use with caution and observe liver enzymes. - Concomitant use with other NMDA antagonists: avoid additive neurotoxicity. - History of seizures: monitor for increased seizure activity. - Cardiovascular disorders: watch for blood pressure changes. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Memantine can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - Ketamine: additive NMDA blockade can lead to excessive CNS depression. - Other NMDA receptor antagonists (e.g., dextromethorphan): avoid concurrent use.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: memantine may enhance hypotensive effects. - Diuretics: increased risk of dizziness or orthostatic hypotension.